We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after November 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CONTROLLED RELEASE ORAL DOSAGE FORM COMPRISING OXYCODONE
Wound dressing comprising non-woven and salve basis for negative pressure therapy
ADDITIVES FOR HYDROGEN/ BROMINE CELLS
PROCESSES FOR PREPARING N-ETHYL-2-METHYLPYRIDINIUM BROMIDE AND N-ETHYL-3-METHYLPYRIDINIUM BROMIDE
CHEMICALLY MODIFIED CELLULOSE FIBROUS MESHES FOR USE AS TISSUE ENGINEERING SCAFFOLDS
DOSAGE FORM COMPRISING LOPINAVIR AND RITONAVIR
DOSAGE FORM COMPRISING NON-CRYSTALLINE LOPINAVIR AND CRYSTALLINE RITONAVIR
MODULATION OF OXIDATIVE STRESS, INFLAMMATION, AND IMPAIRED INSULIN SENSITIVITY WITH GRAPE SEED EXTRACT
ADDITIVES FOR ZINC-BROMINE MEMBRANELESS FLOW CELLS
APPARATUS FOR GASIFICATION OF CARBON CONTAINING FEEDSTOCK INTO SYNGAS BY SUPERHEATED STEAM
DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER
BUFFER SUBSTANCE FOR THE TREATMENT OF WOUNDS
GYPSUM COMPOSITION, GYPSUM SLURRY, GYPSUM HARDENED BODY, GYPSUM-BASED CONSTRUCTION MATERIAL, GYPSUM BOARD, AND METHOD FOR PRODUCING GYPSUM-BASED CONSTRUCTION MATERIAL
Oral dosage form for the immediate release of bendroflumethiazide and controlled release of a second active agent